(197 days)
Not Found
Not Found
No
The description focuses on the mechanical function of the applicator as a guide for radiation delivery and does not mention any computational or analytical capabilities that would suggest AI/ML.
Yes
The device is used to deliver a prescribed radiation dose to a treatment area (prostate), which is a direct therapeutic action in brachytherapy procedures.
No
The device is an applicator set used to deliver radiation during brachytherapy treatment, not to diagnose a condition. It assists in treatment delivery and planning by guiding needles and facilitating imaging for dose determination, but does not perform diagnostic functions itself.
No
The device description clearly details physical components like a template, needles, and fixing screws, which are hardware used in a brachytherapy procedure. It is an accessory to remote afterloading equipment, also hardware.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device Function: The description clearly states that the Nucletron CET Prostate Applicator Set is a physical device used in a brachytherapy procedure. It provides a path for a radioactive source to deliver radiation directly to the prostate tissue.
- No Sample Analysis: The device does not analyze any biological samples from the patient. It is a tool for delivering a therapeutic treatment.
- Imaging for Planning: While imaging (CT, MR) is used in conjunction with the device, it is for treatment planning purposes (determining the precise location of the applicator), not for diagnostic analysis of biological samples.
Therefore, the Nucletron CET Prostate Applicator Set falls under the category of a therapeutic device used in a medical procedure, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
Nucletron CET Prostate Applicator Set is intended for use with the Nucletron remote afterloading equipment: mHDR, mHDR-Classic, mPDR and mLDR, for Interstitial Prostate brachytherapy procedures. The applicator provides a means of delivering the orescribed radiation dose to the treatment area. The applicator is a closed system to prevent the radioactive source from coming in contact with body fluids.
Nucletton CET Prostate Applicator Set is intended for use with Interstitial Prostate brachytherapy procedures involving the Nucletron remote afterloading equipment: mHDR, mHDR-Classic, mPDR and mLDR. The applicator provides a means of delivering the prescribed radiation dose to the treatment area. The applicator is a closed system to prevent the radioactive source from coming in contact with body fluids.
Product codes
90 JAQ
Device Description
The Nucletron CET Prostate Applicator as described in this submission is designed as an accessory to the Nucletron remote afterloading equipment: mHDR, mHDR-Classic, mPDR and mLDR, for Interstitial Prostate brachytherapy procedures.
The CET Prostate Applicator Set consists of a template and needles used for the Interstitial Prostate brachytherapy. The template is sutured to the skin surface and is designed to guide the needles into the prostate tissue. The needle while positioning around the template will anatomically encompass the prostate volume. Once the needles are in position the fixing screws are tightened to immobilize the needles within the tissue. Radiographic images, planar films or transverse slices, i.e. CT, MR are obtained to determine the precise location of the applicator within the body. This information is then used for brachytherapy treatment planning purposes. When the treatment planning is completed the applicator is then attached to the Nucletron remote afterloading equipment (treatment head): mHDR, mHDR-Classic, mPDR and mLDR, by the Nucletron transfer tubes. The transfer tubes lock into the open end of the applicator and the remote afterloading equipment (treatment head) prior to treatment. When the applicator is properly attached, a check cable run is performed to ensure that the applicator is properly attached and that there is no obstructions which will interrupt treatment. After the check cable run, the radioactive source will step through the applicator to deliver that prescribed dose of radiation. When the treatment is complete, the applicator is detached from the transfer tube and remote afterloading equipment. The applicator is then removed from the patient.
The applicator is a closed system to prevent the radioactive source from coming in contact with body fluids. The applicator does not control the treatment unit; it strictly provides a treatment path for the radioactive source. The Nucletron remote afterloading system and the clinical staff verify that the applicator is properly attached prior to treatment.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Radiographic images, planar films or transverse slices, i.e. CT, MR
Anatomical Site
prostate
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Not Found
Key Metrics
Not Found
Predicate Device(s)
Not Found
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 892.5700 Remote controlled radionuclide applicator system.
(a)
Identification. A remote controlled radionuclide applicator system is an electromechanical or pneumatic device intended to enable an operator to apply, by remote control, a radionuclide source into the body or to the surface of the body for radiation therapy. This generic type of device may include patient and equipment supports, component parts, treatment planning computer programs, and accessories.(b)
Classification. Class II.
0
Premarket Notification Nucletron CET Prostate Applicator Set Date : 26 February 1999
OCT 7 1999
Image /page/0/Picture/2 description: The image shows the word "Nucletron" in a bold, sans-serif font. To the left of the word is a square containing a black shape with two white circles. The black shape appears to be a stylized representation of an atom. The overall design is simple and modern.
NUCLETRON B.V. Waardgelder 1 3905 TH Veenendaai P.O.Box 930 3900 AX Veenendaal The Netherlands Phone +31 318 557133 +31 318 550485 Fax
Department of Health and Human Services Center of Device and Radiological Health Office of Device Evaluation Pre-Market Notification Section
510(K) SUMMARY OF SAFETY AND EFFECTIVENESS INFORMATION
as required by section 807.92(c)
Submitter of 510(k) a.
Nucletron Corporation Company name: Registration # 1121753 7080 Columbia Gateway Drive Address: Columbia, MD 21046-2133 Contact Person: Ralph E. Shuping Regulatory Affairs Manager 410-312-4100 Phone:. Fax: 410-312-4197 Device Name: Trade/Proprietary Name: CET Prostate Applicator Set Common/Usual Name:
Classification Name:
Remote Afterloading Interstitial Prostate Brachytherapy Applicator Accessory to remote afterloader 21 CFR 892.5700, Class II.
Legally Marketed Predicate Device(s) C.
Our device is substantially equivalent to the legally marketed predicate device cited in the table below:
| 1 11 50
1 | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | - 4 0 /1 / |
|--------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| . | LEN LE LEBER BLEMILE BALLER BALLER BALLER COLLEGE OF LEE BEAR
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | COLOR CONSULERS OF A SAMERICA CALLERY
ACO010
Company of the children and |
Description ರ.
b.
The Nucletron CET Prostate Applicator as described in this submission is designed as an accessory to the Nucletron remote afterloading equipment: mHDR, mHDR-Classic, mPDR and mLDR, for Interstitial Prostate brachytherapy procedures.
1
Premarket Notification
Nucletron CET Prostate Applicator Set
Date : 26 February 1999
The CET Prostate Applicator Set consists of a template and needles used for the Interstitial Prostate brachytherapy. The template is sutured to the skin surface and is designed to guide the needles into the prostate tissue. The needle while positioning around the template will anatomically encompass the prostate volume. Once the needles are in position the fixing screws are tightened to immobilize the needles within the tissue. Radiographic images, planar films or transverse slices, i.e. CT, MR are obtained to determine the precise location of the applicator within the body. This information is then used for brachytherapy treatment planning purposes. When the treatment planning is completed the applicator is then attached to the Nucletron remote afterloading equipment (treatment head): mHDR, mHDR-Classic, mPDR and mLDR, by the Nucletron transfer tubes. The transfer tubes lock into the open end of the applicator and the remote afterloading equipment (treatment head) prior to treatment. When the applicator is properly attached, a check cable run is performed to ensure that the applicator is properly attached and that there is no obstructions which will interrupt treatment. After the check cable run, the radioactive source will step through the applicator to deliver that prescribed dose of radiation. When the treatment is complete, the applicator is detached from the transfer tube and remote afterloading equipment. The applicator is then removed from the patient.
The applicator is a closed system to prevent the radioactive source from coming in contact with body fluids. The applicator does not control the treatment unit; it strictly provides a treatment path for the radioactive source. The Nucletron remote afterloading system and the clinical staff verify that the applicator is properly attached prior to treatment.
Intended use e.
Nucletron CET Prostate Applicator Set is intended for use with the Nucletron remote afterloading equipment: mHDR, mHDR-Classic, mPDR and mLDR, for Interstitial Prostate brachytherapy procedures. The applicator provides a means of delivering the orescribed radiation dose to the treatment area. The applicator is a closed system to prevent the radioactive source from coming in contact with body fluids.
ಕೆ. Summary of technological considerations
The Nucletron CET Prostate Applicator Set is substantially equivalent to the predicate device. It combines the functionality, components and design of the predicate device while incorporating a new material.
Ludwig Haas
26-2-59
Date
Name: L. A. Johnson Title: Product Manager Nucletron B.V. Veenendaal Netherlands
2
Public Health Service
OCT 7 1999 Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
Ralph Shuping, Sc.D Regulatory Affairs Manager Nucletron Corporation 7080 Columbia Gateway Drive Columbia, Maryland 21046-2133 Re:
K990990 CET Prostate Applicator Set Dated: July 7, 1999 Received: July 9, 1999 Regulatory Class: II 21 CFR 892.5700/Procode: 90 JAQ
Dear Dr. Shuping:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in requlatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdch/dsma/dsmamain.html".
Sincerely yours,
CAPT Daniel G. Schultz, M.D. Acting Director, Division of Reproductive, Abdominal, Ear, Nose and Throat, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
3
Statement of indications for use
510(k) Number (if known): K990990
Device Name: CET Prostate Applicator Set Indications for Use:
Nucletton CET Prostate Applicator Set is intended for use with Interstitial Prostate brachytherapy procedures involving the Nucletron remote afterloading equipment: mHDR, mHDR-Classic, mPDR and mLDR. The applicator provides a means of delivering the prescribed radiation dose to the treatment area. The applicator is a closed system to prevent the radioactive source from coming in contact with body fluids.
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of Device Evaluation (ODE)
| Prescription Use (Per 21 CFR 801.109) | |
|---|---|
| --------------------------------------- | -- |
OR
| Over the Counter Use | |
|---|---|
| ---------------------- | -- |
(Optional Format 1-2-96)
Signature
(Division Sign-Off) Division of Reproductive, Abdominal, EN and Radiological De 510(k) Number